



## Mithra sells Estetra SRL, Neuralis SA and specific assets to Gedeon Richter

- Mithra Pharmaceuticals SA sells all shares held in Neuralis SA and Estetra SRL as well as specific assets of Mithra R&D SA to Gedeon Richter for an aggregate price of EUR 175 million. This transaction was signed and completed on 11 June 2024
- Mithra CDMO and Novalon SA remain under court protection and are therefore not affected by the transaction announced today

**Liège, Belgium, 11 June 2024 – 18:00 CEST** – Mithra (Euronext Brussels: MITRA), a company dedicated to women's health, *under bankruptcy*, today announces that it is selling Gedeon Richter all shares in Neuralis SA and Estetra SRL held by Mithra Pharmaceuticals SA and specific assets held by Mithra R&D SA relating to the manufacture of estetrol. This means the entire business related to the research, development, manufacturing, marketing and post-marketing scientific work relating to estetrol is transferred to Gedeon Richter. Signing and completion of this transaction took place on 11 June 2024.

This transfer includes the related intellectual property rights and current contracts, as well as ESTELLE® (already marketed) and DONESTA® (in development). Gedeon Richter will be responsible for submitting the DONESTA® filing to the agencies and for liaising with the regulatory agencies for the purposes of obtaining marketing authorization and then marketing the product via existing and future contracts.

The Mithra CDMO and Novalon SA entities are not affected by the sale announced today as they are subject to separate judicial reorganization proceedings. The judicial protection measures to which they are subject should, subject to the court's approval, be extended until 30 June 2024. This extension is intended to allow the different parties interested in Mithra CDMO's assets to continue their due diligence and submit binding offers by mid-month.

From an employment point of view, all 49 members of the personnel engaged by the transferred entities will be able to pursue their activities with Gedeon Richter. In addition, 17 other people of Mithra Pharmaceuticals SA have also been offered to join the transferred entities and thus work for Gedeon Richter.

The sale of Neuralis SA and Estetra SRL as well as certain assets of Mithra R&D SA to Gedeon Richter is valued for a total consideration of EUR 175 million. The amount received, after deduction of financial debts, will be used to repay certain amounts to Mithra's creditors in the order of their legal privilege. As a result, this transaction does not create any value for the shareholders of Mithra Pharmaceuticals SA.

### About Mithra

Mithra Pharmaceuticals SA (Euronext: MITRA) is a Belgian biopharmaceutical company dedicated to transforming women's health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill ESTELLE®, Mithra is now focusing on its second product DONESTA®, the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, is headquartered in Liège, Belgium. [www.mithra.com](http://www.mithra.com)

ESTELLE® and DONESTA® are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.

### Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

---